CClinicalTrials.gg
Sign In
Not yet recruitingNCT07683806Updated Aug 21, 2026

Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis

A Phase 3 interventional study of Roflumilast Foam 0.3% and Vehicle foam in Seborrheic Dermatitis, sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Not yet recruiting at 52 sites in China. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
309
Allocation
Randomized
Ages
9 Years and older
Sex
All
01

Study summary

This study will assess the safety and efficacy of Roflumilast foam 0.3% (ZORYVE®) versus vehicle applied once a day for 8 weeks by trial participants with seborrheic dermatitis.

Read the detailed description

This is a phase 3, randomized, parallel group, double blind, vehicle-controlled study in which Roflumilast foam 0.3% (ZORYVE®) or vehicle foam is applied QD for 8 weeks to trial participants 9 years of age and older with seborrheic dermatitis affecting the scalp and/or rest of body.

02

Conditions studied

  • Seborrheic Dermatitis

Browse trials for

Keywords

  • Roflumilast foam
  • seborrheic dermatitis
03

Who can participate

Ages eligible
9 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Males and females ages 9 years and older (inclusive) at the time of consent.
  2. Clinical diagnosis of seborrheic dermatitis of at least 3 months duration at screening as determined by the Investigator. Stable disease for the past 4 weeks.
  3. Seborrheic dermatitis up to 20% BSA involvement. Involvement may be of the scalp and/or face and/or trunk and/or intertriginous areas.
  4. An Investigator Global Assessment (IGA) disease severity of at least moderate ('3') at baseline.
  5. Overall Assessment of Erythema and Overall Assessment of Scaling scores of at least Moderate ('2') at Baseline.
  6. Trial participants in good health as judged by the Investigator, based on medical history, physical examination, vital signs, serum chemistry labs, hematology values, and urinalysis.
  7. Women of Childbearing Potential (WOCBP) must have a negative serum pregnancy test at Screening (Visit 1) and negative urine pregnancy test at Baseline (Visit 2). WOCBP must have used highly effective contraception for at least 4 weeks prior to the first study drug administration, and agree to continue using highly effective contraception for 2 months after the last dose. If hormonal contraceptives are used, the dosage must have been stable for a minimum of 4 weeks before the first administration. Alternatively, WOCBP shall use barrier contraception from the time of signing the ICF through 2 months after the last dose. All WOCBP shall have no plan to conceive or donate oocytes throughout the study period.
  8. Trial participants are considered reliable and capable of adhering to the protocol and visit schedule according to the Investigator judgment.
  9. Participants legally competent to sign and give informed consent or (for children/adolescents) assent with consent of a parent(s) or legal guardian.

Exclusion criteria

Exclusion Criteria:

  1. Trial participants with any serious medical condition or clinically significant laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator.
  2. Any conditions in the treatment area judged by the investigator at screening or baseline that may interfere with efficacy assessment (e.g., confirmed cutaneous bacterial, viral or parasitic infections, psoriasis, atopic dermatitis, acne, as well as pigmentation, extensive scars, pigmentary lesions, sunburn, etc.).
  3. Trial participants with active pityriasis/tinea amiantacea.
  4. Current or history of cancer within 5 years from Screening with the exception of fully treated skin basal cell carcinoma, cutaneous squamous cell carcinoma, or carcinoma in situ of the cervix.
  5. A clinically relevant history of abuse of alcohol or other drugs within 6 months prior to screening.
  6. Known or suspected severe renal insufficiency as evidenced by calculated creatinine clearance \<30 mL/min, or moderate to severe hepatic disorders (Child-Pugh B or C).
  7. History of severe depression, suicidal ideation or behavior, Baseline/Screening C-SSRS (for adolescents and adults 12 years old and older) indicative of suicidal behavior, whether lifetime or recent/recurrent.
  8. Trial participants with PHQ-8 (≥18 years old, inclusive) score ≥10 at Screening or Baseline visits, or children aged 9 to 11 years (inclusive), following discussion with their legal representatives, the investigator assesses the presence of depressive symptoms or suicide/depression risk.
  9. Systemic administration of antifungals, glucocorticoids, immunosuppressants, retinoids, roflumilast tablets, apremilast tablets, or systemic traditional Chinese medicine known or suspected to affect seborrheic dermatitis within 4 weeks prior to the first study drug administration.
  10. Receipt of phototherapy, sunbeds or any other light-emitting devices within 4 weeks prior to the first study drug administration, or planned excessive exposure of the treatment area to natural or artificial light.
  11. Use of topical medications or treatments within 2 weeks prior to the first study drug administration, including but not limited to topical antifungals, topical glucocorticoids, topical calcineurin inhibitors, topical phosphodiesterase 4 (PDE-4) inhibitors, sulfur-containing preparations, azelaic acid, metronidazole, medical devices, or topical traditional Chinese medicine known or suspected to affect seborrheic dermatitis.
  12. Use of medicinal shampoos or medical devices containing antifungals, glucocorticoids, zinc pyrithione, selenium sulfide, coal tar, or keratolytic agents (e.g., salicylic acid) within 2 weeks prior to the first study drug administration.
  13. Receipt of topical treatments on the scalp for indications other than seborrheic dermatitis within 2 weeks prior to the first study drug administration, if such treatments may alter scalp skin conditions (e.g., topical minoxidil for androgenetic alopecia, retinoids or tar preparations for scalp psoriasis, topical anti-allergic agents for allergic dermatitis, and certain oil-control or anti-dandruff shampoos).
  14. Use of potent cytochrome P450 (CYP) 3A4 inhibitors systemically within 2 weeks prior to the first study drug administration.
  15. Intravenous administration of antibiotics or antiviral agents within 1 week prior to the first study drug administration.
  16. Use of etanercept within 4 weeks prior to the first study drug administration, or use of any other biologics within 12 weeks or 5 half-lives (whichever is longer) prior to the first study drug administration.
  17. Participation in any clinical trial of biologics within 12 weeks or 5 half-lives (whichever is longer), any clinical trial of oral formulations within 5 half-lives, or any clinical trial of topical formulations within 2 weeks prior to the first study drug administration (excluding participants who only signed the ICF and did not receive any study drug or device).
  18. Participants who have undergone major surgery within 4 weeks prior to the first study drug administration or are scheduled to receive major surgery during the study period .
  19. Prior use of roflumilast cream or roflumilast foam.
  20. Known allergies or hypersensitivity to component(s) of the investigational product which includes roflumilast, petrolatum, isopropyl palmitate, methylparaben, propylparaben, diethylene glycol monoethyl ether, hexylene glycol, cetearyl alcohol, dicetyl phosphate and ceteth-10 phosphate.
  21. Liver function test results excursions that exceed: AST or ALT > 2x ULN; Total bilirubin: 1.5x ULN or >ULN and ≤1.5x ULN and direct bilirubin is >35% of total bilirubin; ALP ≥ 2x ULN.
  22. History of human immunodeficiency virus (HIV) infection or suspected HIV infection, or positive HIV antibody at screening; positive hepatitis B surface antigen (HBsAg), or negative HBsAg with positive hepatitis B core antibody and HBV-DNA level above the upper limit of normal reference range; positive hepatitis C virus (HCV) antibody with HCV-RNA level above the upper limit of normal reference range; positive treponemal-specific antibody for syphilis (Participants with negative non-specific syphilis antibody and clinically diagnosed as inactive infection may be enrolled). Participants with indeterminate screening results are not recommended for enrollment.
  23. Trial participants/caregivers unable to apply product to the scalp due to physical limitations if the trial participants has current or history of seborrheic dermatitis involving the scalp.
  24. Females who are pregnant, or are breast-feeding.
  25. Trial participants who are family members of the clinical study site, or clinical study staff, or sponsor, or family members residing in the same household of enrolled trial participants.
  26. Trial participants, parent(s)/legal guardian(s) of children/adolescent trial participants who are unable to communicate, read, or understand the study.
  27. Any condition that in the Investigator's assessment would preclude the trial participants from participating in the study
04

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
309 participants (estimated)

Study arms

  • Experimental
    Roflumilast foam 0.3%

    Drug: Roflumilast Foam 0.3%

  • Placebo comparator
    Vehicle foam

    Drug: Vehicle foam

Interventions

  • DrugRoflumilast Foam 0.3%

    Roflumilast foam 0.3% is applied once daily for 8 weeks.

  • DrugVehicle foam

    Vehicle foam is applied once daily for 8 weeks.

05

What researchers measure

Primary outcomes

  1. Percentage of trial participants with IGA success at Week 8

    The IGA is a static evaluation of qualitative overall seborrheic dermatitis severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4). IGA success is defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement.

    Time frame: Baseline, Week 8

Secondary outcomes

  1. Percentage of trial participants with WI-NRS success in subjects with a Baseline WI-NRS pruritus score of ≥4

    The WI-NRS is a simple, single item to assess the patient-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from '0 to 10' ("no itch" to "worst imaginable itch"). WI-NRS success is defined as the achievement of a ≥4-point improvement from baseline in WI-NRS pruritus score.

    Time frame: Baseline, Week 2, Week 4, Week 8

  2. Percentage of trial participants with IGA success at Week 2 and Week 4

    The IGA is a static evaluation of qualitative overall seborrheic dermatitis severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4). IGA success is defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement.

    Time frame: Baseline, Week 2, Week 4

  3. Achievement of an Overall Assessment of Scaling (0-3 scale) score of 0 at Week 8

    Overall Assessment of Scaling are static qualitative evaluations, involving an ordinal scale with 4 severity grades (reported only in integers of 0 to 3). Each grade is defined by a distinct and clinically relevant morphologic description that minimizes inter-observer variability.

    Time frame: Baseline, Week 8

  4. Achievement of an Overall Assessment of Erythema (0-3 scale) score of 0 at Week 8

    Overall Assessment of Erythema is a static qualitative evaluation, involving an ordinal scale with 4 severity grades (reported only in integers of 0 to 3). Each grade is defined by a distinct and clinically relevant morphologic description that minimizes inter-observer variability.

    Time frame: Baseline, Week 8

  5. Achievement of an IGA score of 0 at Week 8

    The IGA is a static evaluation of qualitative overall seborrheic dermatitis severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4). IGA score of 0 is described as no erythema, no scaling (hypo-hyperpigmentation can be present).

    Time frame: Baseline, Week 8

  6. Safety: TEAE

    Treatment-emergent adverse events (TEAEs), including details regarding incidence, severity, time of onset, duration, causality to the investigational product, clinical outcome, and actions taken with the study treatment.

    Time frame: Throughout the study, up to 9 weeks

  7. Safety: Other Safety Endpoint

    Numbers of participants with any of the followings: local intolerability, abnormal vital signs (including body temperature, pulse rate, respiratory rate, and blood pressure), weight loss of \>5% from baseline, hypopigmentation and/or hyperpigmentation, abnromal laboratory tests (including hematology, chemistry, and urinalysis), abnormal Patient Health Questionnaire Depression Scale (PHQ-8)/modified Adolescent Patient Health Questionnaire Depression Scale (PHQ-A), and/or Columbia Suicide Severity Rating Scale (C-SSRS).

    Time frame: Up to 8 weeks.

  8. Pharmacokinetic (PK) endpoint

    To analyze the trough plasma concentrations of Roflumilast and its N-oxide at Week 4 and Week 8 after administration.

    Time frame: Up to 8 weeks.

Other outcomes

  1. Achievement of an Overall Assessment of Scaling score of 0 at Week 2 and Week 4

    Overall Assessment of Scaling are static qualitative evaluations, involving an ordinal scale with 4 severity grades (reported only in integers of 0 to 3). Each grade is defined by a distinct and clinically relevant morphologic description that minimizes inter-observer variability.

    Time frame: Baseline, Week 2, Week 4

  2. Achievement of an Overall Assessment of Erythema score of 0 at Week 2 and Week 4

    Overall Assessment of Erythema is a static qualitative evaluation, involving an ordinal scale with 4 severity grades (reported only in integers of 0 to 3). Each grade is defined by a distinct and clinically relevant morphologic description that minimizes inter-observer variability.

    Time frame: Baseline, Week 2, Week 4

  3. Absolute changes from baseline in Scalpdex score at Week 2, Week 4, and Week 8

    The Scalpdex score is used to assess the severity of scalp disorders.

    Time frame: Baseline, Week 2, Week 4, Week 8

  4. Absolute change from baseline in DLQI/CDLQI score at Week 2, Week 4, Week 8

    The DLQI/CDLQI is a simple, self-administered and user-friendly validated questionnaire. The DLQI/CDLQI is designed to measure the health-related quality of life of patients suffering from a skin disease. The DLQI/CDLQI consists of 10 questions concerning patients' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week. The DLQI will be completed by participants ages 17 years and older. The CDLQI will be completed by caregivers of participants ages 9-16 years.

    Time frame: Baseline, Week 2, Week 4, Week 8

  5. Absolute change from baseline in BSA at Week 2, Week 4, Week 8

    The BSA affected by seborrheic dermatitis will be determined by the participant's hand method, where the participant's hand (including fingers) surface area is assumed to equal 1% of body surface area.

    Time frame: Baseline, Week 2, Week 4, Week 8

  6. Absolute change from baseline in Overall Assessment of Erythema at Week 2, Week 4, Week 8

    Overall Assessment of Erythema is a static qualitative evaluation, involving an ordinal scale with 4 severity grades (reported only in integers of 0 to 3).

    Time frame: Baseline, Week 2, Week 4, Week 8

  7. Absolute change from baseline in Overall Assessment of Scaling at Week 2, Week 4, Week 8

    Overall Assessment of Scaling are static qualitative evaluations, involving an ordinal scale with 4 severity grades (reported only in integers of 0 to 3).

    Time frame: Baseline, Week 2, Week 4, Week 8

  8. Absolute change from baseline in Weekly average WI-NRS score at Week 2, Week 4, Week 8

    The WI-NRS will be determined by asking the participant's assessment of worst itch over the past 24 hours. The scale is from '0 to 10' ("no itch" to "worst imaginable itch").

    Time frame: Baseline, Week 2, Week 4, Week 8

  9. Percentage change from baseline in Scalpdex score at Week 2, Week 4, and Week 8

    The Scalpdex score is used to assess the severity of scalp disorders.

    Time frame: Baseline, Week 2, Week 4, Week 8

  10. Percentage change from baseline in DLQI/CDLQI score at Week 2, Week 4, and Week 8

    The DLQI/CDLQI is a simple, self-administered and user-friendly validated questionnaire. The DLQI/CDLQI is designed to measure the health-related quality of life of patients suffering from a skin disease. The DLQI/CDLQI consists of 10 questions concerning patients' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week. The DLQI will be completed by participants ages 17 years and older. The CDLQI will be completed by caregivers of participants ages 9-16 years.

    Time frame: Baseline, Week 2, Week 4, Week 8

  11. Percentage change from baseline in BSA at Week 2, Week 4, and Week 8

    The BSA affected by seborrheic dermatitis will be determined by the participant's hand method, where the participant's hand (including fingers) surface area is assumed to equal 1% of body surface area.

    Time frame: Baseline, Week 2, Week 4, Week 8

  12. Percentage change from baseline in Overall Assessment of Erythema at Week 2, Week 4, and Week 8

    Overall Assessment of Erythema is a static qualitative evaluation, involving an ordinal scale with 4 severity grades (reported only in integers of 0 to 3).

    Time frame: Baseline, Week 2, Week 4, Week 8

  13. Percentage change from baseline in Overall Assessment of Scaling at Week 2, Week 4, and Week 8

    Overall Assessment of Scaling are static qualitative evaluations, involving an ordinal scale with 4 severity grades (reported only in integers of 0 to 3).

    Time frame: Baseline, Week 2, Week 4, Week 8

  14. Percentage change from baseline in Weekly average WI-NRS score at Week 2, Week 4, and Week 8

    The WI-NRS will be determined by asking the participant's assessment of worst itch over the past 24 hours. The scale is from '0 to 10' ("no itch" to "worst imaginable itch").

    Time frame: Baseline, Week 2, Week 4, Week 8

  15. Percentage of trial participants with daily WI-NRS score of 0 or 1

    The WI-NRS is a simple, single item to assess the patient-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from '0 to 10' ("no itch" to "worst imaginable itch").

    Time frame: Up to 8 weeks.

  16. Percentage of trial participants with an IGA score of 0 at Week 2 and Week 4

    The IGA is a static evaluation of qualitative overall seborrheic dermatitis severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4).

    Time frame: Baseline, Week 2, Week 4

06

Study locations

52 sites
  • The First Affiliated Hospital of Bengbu Medical University
    Bengbu, Anhui, China
  • The First Affiliated Hospital of Wannan Medical Hospital
    Wuhu, Anhui, China
  • The Second Affiliated Hospital of Wannan Medical University
    Wuhu, Anhui, China
  • The first affilated hospital of Fujian Medical university
    Fuzhou, Fujian, China
  • The Second Affiliated Hospital of Xiamen Medical College
    Xiamen, Fujian, China
  • Dermatology Hospital of Southern Medical University
    Guangzhou, Guangdong, China
  • Shenzhen Children's Hospital
    Shenzhen, Guangdong, China
  • Hainan Fifth People's Hospital
    Haikou, Hainan, China
  • Beijing Children's Hospital, Capital Medical University Baoding Hospital
    Baoding, Hebei, China
  • The Second Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang, China
  • The Second Affiliated Hospital of Henan University of science and technology
    Luoyang, Henan, China
  • Nanyang Central Hospital
    Nanyang, Henan, China
  • Sanmenxia Central Hospital
    Sanmenxia, Henan, China
  • Zhengzhou Central Hospital
    Zhenzhou, Henan, China
  • Jingzhou Central Hospital
    Jingzhou, Hubei, China
  • Jingzhou First People's Hospital
    Jingzhou, Hubei, China
  • Shiyan People's Hospital
    Shiyan, Hubei, China
  • Yichang Central People's Hospital
    Yichang, Hubei, China
  • The First People's Hospital of Changde
    Changde, Hunan, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • The First Affiliated Hospital Of University Of South China
    Hengyang, Hunan, China
  • Sir Run Run Hospital,Nanjing Medical University
    Nanjing, Jiangsu, China
  • Wuxi No. 2 People's Hospital
    Wuxi, Jiangsu, China
  • Yancheng No.1 People's Hospital
    Yancheng, Jiangsu, China
  • Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu, China
  • Second Hospital of Jilin University
    Changchun, Jilin, China
  • Central Hospital Affiliated to Shenyang Medical College
    Shenyang, Liaoning, China
  • Liaoning Provincial People's Hospital
    Shenyang, Liaoning, China
  • Jinan Municipal Central Hospital
    Jinan, Shandong, China
  • Shandong First Medical University Affiliated Hospital of Dermatology
    Jinan, Shandong, China
  • Taiyuan Central Hospital
    Taiyuan, Shanxi, China
  • Shanxi Yuncheng Central Hospital
    Yuncheng, Shanxi, China
  • Chengdu Second People's Hospital
    Chengdu, Sichuan, China
  • Chengdu Women's Children's Central Hospital
    Chengdu, Sichuan, China
  • huan Academy of Medical Sciences & Sichuan Provincial People's Hospital
    Chengdu, Sichuan, China
  • Hangzhou First People's Hospital
    Hangzhou, Zhejiang, China
  • Hangzhou Third People's Hospital
    Hangzhou, Zhejiang, China
    • Xiuzu Song · Contact · hz3ygcp@163.com · 0571-87823189
    • Xingang Wu · Contact
  • Zhejiang Provincial People's Hospital
    Hangzhou, Zhejiang, China
  • The First Hospital of Jiaxing
    Jiaxing, Zhejiang, China
  • Ningbo No.2 Hospital
    Ningbo, Zhejiang, China
  • The Fourth Affiliated Hospital, Zhejiang University School of Medicine
    Yiwu, Zhejiang, China
  • Beijing Aerospace General Hospital
    Beijing, China
  • Beijing Children's Hospital, Capital Medical University Baoding Hospital
    Beijing, China
  • Beijing Huairou Hospital
    Beijing, China
  • China-Japan Friendship Hospital
    Beijing, China
  • Peking University People's Hospital
    Beijing, China
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, China
  • Children's Hospital of Shanghai
    Shanghai, China
  • Huashan Hospital, Fudan University
    Shanghai, China
  • Shanghai Dermatology Hospital
    Shanghai, China
  • Shanghai General Hospital
    Shanghai, China
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07683806
Lead sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Collaborators
Arcutis Biotherapeutics, Inc.
Responsible party
Sponsor
First posted
Jul 6, 2026
Start date
Aug 24, 2026 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Aug 3, 2027 (estimated)
Last update
Aug 21, 2026

Study contacts

Huadong Medicine
Contact
cxyguweizhi@eastchinapharm.com
+86-0571-89918267

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Dermatitis, Seborrheic→

Other studies from this sponsor

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Start the discussion